The past week Gubra A/S went public on the main stock exchange in Copenhagen, raising 500 MDKK. The share price for Gubra is currently trading around the offer price of 110 DKK.
11 of the 19 listed, Danish biotech companies have published news the past week. 11 of the companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date.
Company news the past week
Ascendis Pharma
No news past week
Biosergen provides Phase 2 clinical development strategy update (LINK)
Biosergen Q4 EBITDA Loss Widens To SEK 12.5 Mln – Significant Developments (LINK)
Cessatech
No news past week
CS MEDICA A/S: Notice of Extraordinary General Meeting (LINK)
CS MEDICA has entered into agreement with investor regarding directed share issue of DKK 60M at DKK 28.13 per share (LINK)
CS MEDICA has entered a joint venture regarding production of CS-MEDICA’s CANNASEN® CBD medical products in China and distribution of CANNASEN® CBD products to the Asian market (LINK)
Medical Device Company Approved to Prolong MDR Transition Until 31. December 2028 (LINK)
No news past week
Evaxion Biotech
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients. (LINK)
Expres2ion
ExpreS2ion to participate in upcoming events. (LINK)
ExpreS2ion publishes prospectus in connection with its rights issue of units (LINK)
Fluoguide
No news past week
Genmab
Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer (LINK)
Gubra
Gubra announces the result of its initial public offering (LINK)
Initiator Pharma
No news past week
IO Biotech
No news past week
Pila Pharma
XEN-D0501 can progress to clinical trials up to 3-month duration after being found safe in 13-week preclinical oral safety studies. (LINK)
Saniona
No news past week
Scandion Oncology
Scandion Oncology – Annual Report 2022 (LINK)
Scandion Oncology successfully completes the dose finding with lead compound SCO-101 in advanced pancreatic cancer patients (PANTAX phase Ib trial) (LINK)
SynAct Pharma
SynAct Pharma introduces resomelagon as generic name for AP1189 (LINK)
SynAct Pharma to host a Capital Markets Day in Stockholm on May 5, 2023 (LINK)
ViroGates
ViroGates A/S – ViroGates announces the publication of a new study that shows suPAR causes cardiovascular disease (LINK)
Zealand Pharma
Increases its Share Capital as a Consequence of Exercise of Employee Warrants (LINK)
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396 (LINK)
Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion (LINK)
Y-mAbs Therapeutics
No news past week
2cureX
No news past week
Share price development
Y-mAbs Therapeutics Inc. became the best performing Danish biotech company last week with a 65% increase, even though they didn’t publish any news. At the opposite end of the spectrum was Expres2Ion Biotech Holding AB, which fell 10% after publishing the prospectus in connection with its rights issue of units. Since the start of the year, most of the companies have been under pressure, while especially Saniona AB, Curasight A/S and Fluoguide AB has performed very well. Saniona has made a strong comeback after several years of downturns. This follows after a possible approval for the company’s lead-candidate in Mexcio, which could generate royalties for Saniona.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
